Nyxoah Reports Q2 Loss with 74% Revenue Growth, Genio® U.S. Launch; Opthea Cuts 80% Staff to Avert Bankruptcy

Nyxoah reported its second-quarter 2025 financial and operating results, revealing an earnings per share of approximately -$0.60 (-€0.55) and revenue of around $1.41 million (€1.3 million). Despite a net loss of approximately $22.4 million (€20.6 million), the company highlighted a 74% year-over-year revenue growth and noted that the FDA has approved its Genio® system for the U.S. market, with a commercial launch currently underway. OS Therapies also released its second-quarter 2025 financial results and provided a business update. HCW Biologics announced its second-quarter 2025 business highlights and financial results. In contrast, Australian biopharmaceutical company Opthea disclosed a major corporate restructuring, cutting 80% of its staff and seeing key executives exit as part of a deal to avoid bankruptcy.